Mind Medicine (MindMed) Inc. MNMD
Apr 2, 2026, 3:59 PM EDT
52-week range unavailable
- YTD
- +54.52%
- 1 year
- +219.78%
- Market cap
- 1.56B
- YTD return
- +54.52%
- 1-year return
- +219.78%
- Volume
- 298.41K
- Open
- 20.15
- Previous close
- 20.69
- Day's range
- 19.95 – 21.10
- Earnings date
- May 7, 2026
Key statistics
- Enterprise value
- 3.69B
- PEG ratio
- 0.13
- Price / sales
- 0.00
- Price / book
- 3.86
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -85.23%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy7
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
May 7, 2026
Expected May 7, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 7, 2026 | Mar 31, 2026 | -0.478 | — | — | — |
| Mar 5, 2026 | Dec 31, 2025 | -0.48 | -0.51 | -0.03 | -6.25% |
| Nov 6, 2025 | Sep 30, 2025 | -0.52 | -0.78 | -0.26 | -50.00% |
| Jul 31, 2025 | Jun 30, 2025 | -0.38 | -0.50 | -0.12 | -31.58% |
| May 8, 2025 | Mar 31, 2025 | -0.36 | -0.35 | +0.01 | +2.78% |
| Mar 6, 2025 | Dec 31, 2024 | -0.33 | -0.41 | -0.08 | -24.24% |
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum disorder. Its corporate headquarters are situated in Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- CA
- Employees
- 74
- Website
- definiumtx.com
News
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order 
'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment 
Short Interest in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Grows By 19.4% 
Mind Medicine (MindMed) Inc. (MNMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript 
Mind Medicine (MindMed) (NASDAQ:MNMD) CEO Robert Barrow Sells 25,791 Shares of Stock 
MNMD Stock Up More Than 100% in 6 Months: What's in Store for 2026? 
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Rating of “Buy” from Analysts 
MindMed to Present at the 44th Annual J.P. Morgan Healthcare Conference 
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 
MindMed Announces New Employee Inducement Grant
Your note
Sign in to keep a note on MNMD — it syncs with the Stock Master app.